Recordati gains certain rights to Apricus' Vitaros

10 February 2014

Italian drugmaker Recordati (RC: MI) has signed an exclusive license agreement with the USA’s Apricus Biosciences (Nasdaq: APRI) for the marketing and sales of Vitaros (alprostadil), for the treatment of erectile dysfunction.

Territories assigned to Recordati include certain European countries, among others, Spain, European Union member countries in Central and Eastern Europe, Russia and the Commonwealth of Independent States (CIS), Turkey and certain African countries.

Paying $3.8 million upfront plus $47 million in milestones

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK